XML 16 R6.htm IDEA: XBRL DOCUMENT v3.23.2
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Operating activities:    
Net loss $ (3,775) $ (2,266)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation of property and equipment 26 59
Amortization of intangible assets 76 182
Modification of common stock warrants, included in Other expense 285 0
Non-cash gain on changes in fair value of warrant liability (216) (2,056)
Non-cash gain on changes in fair value of combined derivative liability (40) (0)
Non-cash gain on changes in fair value of contingent liability 0 (219)
Accretion of interest and amortization of debt discounts on convertible notes 457 0
Changes in operating assets and liabilities:    
Accounts receivable (650) 570
Inventory (223) (581)
Prepaid expenses and other current assets 41 149
Operating lease right-of-use assets 195 (1,806)
Other assets (15) 0
Accounts payable and accrued liabilities 432 50
Operating lease liabilities (186) 1,824
Net cash used in operating activities (3,454) (3,756)
Investing activities:    
Purchases of property and equipment (15) (32)
Net cash used in investing activities (15) (32)
Financing activities:    
Proceeds from convertible notes and warrant issuances, net of discount 3,000 0
Payment on the convertible notes (193) 0
Debt issuance cost (294) 0
Payment on the line of credit 0 (105)
Net cash provided by (used in) financing activities 2,513 (105)
Net change in cash, cash equivalents, and restricted cash (956) (3,893)
Cash, cash equivalents and restricted cash, beginning of year 5,846 7,979
Cash, cash equivalents and restricted cash, end of period 4,890 4,086
Interest paid 9 7
Warrant liability transferred to equity 1,360 7,502
Addition of operating lease, right-of-use asset 0 2,039
Employees and Directors [Member]    
Adjustments to reconcile net loss to net cash used in operating activities:    
Stock-based compensation expense related to employee and director stock awards 139 338
Conversion of Series B Preferred Stock to Common Stock [Member]    
Financing activities:    
Conversion of Preferred Stock to common stock 121 110
Conversion of Series C Preferred Stock to Common Stock [Member]    
Financing activities:    
Conversion of Preferred Stock to common stock $ 728 $ 0